Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Strickler

Showing results (41-50 of 100) with videos related to

Pageof 10
Sort By:
JCO Precision Oncology|January 21, 2026
Prevalence and Clinical Characteristics of Germline Epidermal Growth Factor Receptor Mutations in the Southeastern Unites StatesJenny O'Brien, Ryne C Ramaker, Ashley Moyer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 30, 2021
A Phase 1a/b Open-Label, Dose-Escalation Study of Etigilimab Alone or in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid TumorsNiharika B Mettu, Susanna V Ulahannan, Johanna C Bendell, et al.
Molecular Therapy. Oncology|January 16, 2026
Safety and feasibility of talimogene laherparepvec in peritoneal surface malignancies: Results from the TEMPO trialJohn H Stewart, Donna Niedzwiecki, Melissa Lowe, et al.
Clinical Colorectal Cancer|January 2, 2019
Third- or Later-line Therapy for Metastatic Colorectal Cancer: Reviewing Best PracticeTanios Bekaii-Saab, Richard Kim, Tae Won Kim, et al.
Future Oncology (London, England)|December 26, 2024
MOUNTAINEER-03 phase III study design: first-line mFOLFOX6 + tucatinib + trastuzumab for HER2+ metastatic colorectal cancerJohn H Strickler, Tanios Bekaii-Saab, Andrea Cercek, et al.
Journal of the National Cancer Institute|February 6, 2024
Racial and ethnic disparities in genomic testing among lung cancer patients: a systematic reviewClare Meernik, Yadurshini Raveendran, Michaela Kolarova, et al.
ESMO Open|January 1, 2026
Immune checkpoint blockade in locally advanced rectal cancer with deficient DNA mismatch repair: retrospective multicenter experienceO E Emiloju, N R Foster, P Shah, et al.
JCO Precision Oncology|September 27, 2021
Implementation of a Molecular Tumor Registry to Support the Adoption of Precision Oncology Within an Academic Medical Center: The Duke University ExperienceMichelle F Green, Jonathan L Bell, Christopher B Hubbard, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|August 7, 2023
Real-World Treatment Patterns in Patients With HER2-Amplified Metastatic Colorectal Cancer: A Clinical-Genomic Database StudyJohn H Strickler, Ling-I Hsu, Phoebe Wright, et al.
Cell Reports|May 5, 2021
Pharmacological Wnt ligand inhibition overcomes key tumor-mediated resistance pathways to anti-PD-1 immunotherapyNicholas C DeVito, Michael Sturdivant, Balamayooran Thievanthiran, et al.
Pageof 10

Showing results (41-50 of 100) with videos related to

Sort By:
Pageof 10
JCO Precision Oncology|January 21, 2026
Prevalence and Clinical Characteristics of Germline Epidermal Growth Factor Receptor Mutations in the Southeastern Unites StatesJenny O'Brien, Ryne C Ramaker, Ashley Moyer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 30, 2021
A Phase 1a/b Open-Label, Dose-Escalation Study of Etigilimab Alone or in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid TumorsNiharika B Mettu, Susanna V Ulahannan, Johanna C Bendell, et al.
Molecular Therapy. Oncology|January 16, 2026
Safety and feasibility of talimogene laherparepvec in peritoneal surface malignancies: Results from the TEMPO trialJohn H Stewart, Donna Niedzwiecki, Melissa Lowe, et al.
Clinical Colorectal Cancer|January 2, 2019
Third- or Later-line Therapy for Metastatic Colorectal Cancer: Reviewing Best PracticeTanios Bekaii-Saab, Richard Kim, Tae Won Kim, et al.
Future Oncology (London, England)|December 26, 2024
MOUNTAINEER-03 phase III study design: first-line mFOLFOX6 + tucatinib + trastuzumab for HER2+ metastatic colorectal cancerJohn H Strickler, Tanios Bekaii-Saab, Andrea Cercek, et al.
Journal of the National Cancer Institute|February 6, 2024
Racial and ethnic disparities in genomic testing among lung cancer patients: a systematic reviewClare Meernik, Yadurshini Raveendran, Michaela Kolarova, et al.
ESMO Open|January 1, 2026
Immune checkpoint blockade in locally advanced rectal cancer with deficient DNA mismatch repair: retrospective multicenter experienceO E Emiloju, N R Foster, P Shah, et al.
JCO Precision Oncology|September 27, 2021
Implementation of a Molecular Tumor Registry to Support the Adoption of Precision Oncology Within an Academic Medical Center: The Duke University ExperienceMichelle F Green, Jonathan L Bell, Christopher B Hubbard, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|August 7, 2023
Real-World Treatment Patterns in Patients With HER2-Amplified Metastatic Colorectal Cancer: A Clinical-Genomic Database StudyJohn H Strickler, Ling-I Hsu, Phoebe Wright, et al.
Cell Reports|May 5, 2021
Pharmacological Wnt ligand inhibition overcomes key tumor-mediated resistance pathways to anti-PD-1 immunotherapyNicholas C DeVito, Michael Sturdivant, Balamayooran Thievanthiran, et al.
Pageof 10